LFG
TNGX icon

Larson Financial Group’s Tango Therapeutics TNGX Stock Holding History

Larson Financial Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.23K Buy
250
+216
+635% +$3.01K ﹤0.01% 2585
2025
Q4 		$301 Buy
+34
New +$293 ﹤0.01% 3211

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Larson Financial Group's TNGX Position: Q1 2026 in Review

Larson Financial Group increased its Tango Therapeutics (TNGX) stake by 635% in Q1 2026, buying an estimated $3.01K and bringing the position to 250 shares worth $5.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2585.

Larson Financial Group first reported a position in TNGX in Q4 2025 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Larson Financial Group held 250 shares of Tango Therapeutics worth $5.23K as of Q1 2026.
  • Larson Financial Group bought 216 Tango Therapeutics shares in Q1 2026, an estimated $3.01K.
  • Tango Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2585 holding.
  • Larson Financial Group first reported a position in Tango Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.